Nevertheless, we did not detect evidence of a benefit from 1 to 3 months of DAPT followed by P2Y12 inhibitor monotherapy with respect to MACEs compared with DAPT among these patients, irrespective of the presentation of renal dysfunction. This evidence concerns the gene P2RY12 and Abnormal renal physiology.